Mutations in specific genes, including synuclein alpha (SNCA) that encodes the α-synuclein protein, are known to be risk factors for sporadic Parkinson's disease (PD), as well as critical factors for familial PD. In particular, A53T-mutated SNCA (A53T-SNCA) is a well-studied familial pathologic mutation in PD. However, techniques for deletion of the mutated SNCA gene in vivo have not been developed. Here, we used the CRISPR-Cas9 system to delete A53T-SNCA in vitro as well as in vivo. Adeno-associated virus carrying SaCas9-KKH with a single-guide RNA targeting A53T-SNCA significantly reduced A53T-SNCA expression levels in vitro. Furthermore, we tested its therapeutic potential in vivo in a viral A53T-SNCA-overexpressing rat model of PD. Gene deletion of A53T-SNCA significantly rescued the overexpression of α-synuclein, reactive microgliosis, dopaminergic neurodegeneration, and parkinsonian motor symptoms. Our findings propose CRISPR-Cas9 system as a potential prevention strategy for A53T-SNCA-specific PD.
SatakeW, NakabayashiY, MizutaI, et al.Genome-wide association study identifies common variants at four loci as genetic risk factors for Parkinson's disease. Nat Genet, 2009; 41:1303–1307. DOI: 10.1038/ng.485.
3.
Simon-SanchezJ, SchulteC, BrasJM, et al.Genome-wide association study reveals genetic risk underlying Parkinson's disease. Nat Genet, 2009; 41:1308–1312. DOI: 10.1038/ng.487.
4.
SharmaM, IoannidisJP, AaslyJO, et al.Large-scale replication and heterogeneity in Parkinson disease genetic loci. Neurology, 2012; 79:659–667. DOI: 10.1212/WNL.0b013e318264e353.
5.
PolymeropoulosMH, LavedanC, LeroyE, et al.Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science, 1997; 276:2045–2047. DOI: 10.1126/science.276.5321.2045.
6.
SpiraPJ, SharpeDM, HallidayG, et al.Clinical and pathological features of a Parkinsonian syndrome in a family with an Ala53Thr alpha-synuclein mutation. Ann Neurol, 2001; 49:313–319.
7.
VermilyeaSC, EmborgME. Alpha-Synuclein and nonhuman primate models of Parkinson's disease. J Neurosci Methods, 2015; 255:38–51. DOI: 10.1016/j.jneumeth.2015.07.025.
8.
IpCW, KlausLC, KarikariAA, et al.AAV1/2-induced overexpression of A53T-alpha-synuclein in the substantia nigra results in degeneration of the nigrostriatal system with Lewy-like pathology and motor impairment: a new mouse model for Parkinson's disease. Acta Neuropathol Commun, 2017; 5:11. DOI: 10.1186/s40478-017-0416-x.
9.
SatoH, ArawakaS, HaraS, et al.Authentically phosphorylated alpha-synuclein at Ser129 accelerates neurodegeneration in a rat model of familial Parkinson's disease. J Neurosci, 2011; 31:16884–16894. DOI: 10.1523/JNEUROSCI.3967-11.2011.
10.
HeoJY, NamMH, YoonHH, et al.Aberrant tonic inhibition of dopaminergic neuronal activity causes motor symptoms in animal models of Parkinson's disease. Curr Biol, 2020; 30:276–291.e9. DOI: 10.1016/j.cub.2019.11.079.
11.
KirikD, RosenbladC, BurgerC, et al.Parkinson-like neurodegeneration induced by targeted overexpression of alpha-synuclein in the nigrostriatal system. J Neurosci, 2002; 22:2780–2791. DOI: 10.1523/JNEUROSCI.22-07-02780.2002.
12.
ChoSW, KimS, KimJM, et al.Targeted genome engineering in human cells with the Cas9 RNA-guided endonuclease. Nat Biotechnol, 2013; 31:230–232. DOI: 10.1038/nbt.2507.
13.
JiangW, BikardD, CoxD, et al.RNA-guided editing of bacterial genomes using CRISPR-Cas systems. Nat Biotechnol, 2013; 31:233–239. DOI: 10.1038/nbt.2508.
14.
RyuSM, HurJW, KimK. Evolution of CRISPR towards accurate and efficient mammal genome engineering. BMB Rep, 2019; 52:475–481 DOI: 10.5483/BMBRep.2019.52.8.149.
15.
BaeT, HurJW, KimD, et al.Recent trends in CRISPR-Cas system: genome, epigenome, and transcriptome editing and CRISPR delivery systems. Genes Genomics, 2019; 41:871–877. DOI: 10.1007/s13258-019-00830-w.
16.
MingozziF, HighKA. Therapeutic in vivo gene transfer for genetic disease using AAV: progress and challenges. Nat Rev Genet, 2011; 12:341–355. DOI: 10.1038/nrg2988.
SenísE, FatourosC, GroßeS, et al.CRISPR/Cas9-mediated genome engineering: an adeno-associated viral (AAV) vector toolbox. Biotechnol J, 2014; 9:1402–1412. DOI: 10.1002/biot.201400046.
20.
RanFA, CongL, YanWX, et al.In vivo genome editing using Staphylococcus aureus Cas9. Nature, 2015; 520:186–191. DOI: 10.1038/nature14299.
21.
NelsonCE, HakimCH, OusteroutDG, et al.In vivo genome editing improves muscle function in a mouse model of Duchenne muscular dystrophy. Science, 2016; 351:403–407. DOI: 10.1126/science.aad5143.
22.
LongC, AmoasiiL, MireaultAA, et al.Postnatal genome editing partially restores dystrophin expression in a mouse model of muscular dystrophy. Science, 2016; 351:400–403. DOI: 10.1126/science.aad5725.
23.
TabebordbarM, ZhuK, ChengJK, et al.In vivo gene editing in dystrophic mouse muscle and muscle stem cells. Science, 2016; 351:407–411. DOI: 10.1126/science.aad5177.
24.
KleinstiverBP, PrewMS, TsaiSQ, et al.Broadening the targeting range of Staphylococcus aureus CRISPR-Cas9 by modifying PAM recognition. Nat Biotechnol, 2015; 33:1293–1298. DOI: 10.1038/nbt.3404.
25.
RyuS-M, HurJW, KimK. Evolution of CRISPR towards accurate and efficient mammal genome engineering. BMB Rep, 2019; 52:475–481. DOI: 10.5483/BMBRep.2019.52.8.149.
26.
VilligerL, Grisch-ChanHM, LindsayH, et al.Treatment of a metabolic liver disease by in vivo genome base editing in adult mice. Nat Med, 2018; 24:1519–1525. DOI: 10.1038/s41591-018-0209-1.
27.
MollaKA, YangY. CRISPR/Cas-mediated base editing: technical considerations and practical applications. Trends Biotechnol, 2019; 37:1121–1142. DOI: 10.1016/j.tibtech.2019.03.008.
28.
YinH, SongC-Q, DorkinJR, et al.Therapeutic genome editing by combined viral and non-viral delivery of CRISPR system components in vivo. Nat Biotechnol, 2016; 34:328–333. DOI: 10.1038/nbt.3471.
29.
FrangoulH, AltshulerD, CappelliniMD, et al.CRISPR-Cas9 gene editing for sickle cell disease and β-thalassemia. New Engl J Med, 2021; 384:252–260. DOI: 10.1056/NEJMoa2031054.
30.
LeeJ, BayarsaikhanD, ArivazhaganR, et al.CRISPR/Cas9 edited sRAGE-MSCs protect neuronal death in Parkinson's disease model. Int J Stem Cells, 2019; 12:114–124. DOI: 10.15283/ijsc18110.
31.
SafariF, HatamG, BehbahaniAB, et al.CRISPR system: a high-throughput toolbox for research and treatment of Parkinson's disease. Cell Mol Neurobiol, 2020; 40:477–493. DOI: 10.1007/s10571-019-00761-w.
32.
LuoJ, PadhiP, JinH, et al.Utilization of the CRISPR-Cas9 gene editing system to dissect neuroinflammatory and neuropharmacological mechanisms in Parkinson's disease. J Neuroimmune Pharmacol, 2019; 14:595–607. DOI: 10.1007/s11481-019-09844-3.
33.
GordonR, NealML, LuoJ, et al.Prokineticin-2 upregulation during neuronal injury mediates a compensatory protective response against dopaminergic neuronal degeneration. Nat Commun, 2016; 7:12932. DOI: 10.1038/ncomms12932.
34.
KleinstiverBP, PrewMS, TsaiSQ, et al.Engineered CRISPR-Cas9 nucleases with altered PAM specificities. Nature, 2015; 523:481–485. DOI: 10.1038/nature14592.
35.
TóthE, CzeneBC, KulcsárPI, et al.Mb-and FnCpf1 nucleases are active in mammalian cells: activities and PAM preferences of four wild-type Cpf1 nucleases and of their altered PAM specificity variants. Nucleic Acids Res, 2018; 46:10272–10285. DOI: 10.1093/nar/gky815.
36.
GrimmD, LeeJS, WangL, et al.In vitro and in vivo gene therapy vector evolution via multispecies interbreeding and retargeting of adeno-associated viruses. J Virol, 2008; 82:5887–5911. DOI: 10.1128/JVI.00254-08.
37.
NamMH, ChoJ, KwonDH, et al.Excessive astrocytic GABA causes cortical hypometabolism and impedes functional recovery after subcortical stroke. Cell Rep, 2020; 32:107861. DOI: 10.1016/j.celrep.2020.107861.
38.
SchallertT, FlemingSM, LeasureJL, et al.CNS plasticity and assessment of forelimb sensorimotor outcome in unilateral rat models of stroke, cortical ablation, parkinsonism and spinal cord injury. Neuropharmacology, 2000; 39:777–787. DOI: 10.1016/s0028-3908(00)00005-8.
39.
YoonHH, ParkJH, KimYH, et al.Optogenetic inactivation of the subthalamic nucleus improves forelimb akinesia in a rat model of Parkinson disease. Neurosurgery, 2014; 74:533–540; discussion 540–531. DOI: 10.1227/NEU.0000000000000297.
40.
BoixJ, von HieberD, ConnorB. Gait analysis for early detection of motor symptoms in the 6-OHDA rat model of Parkinson's disease. Front Behav Neurosci, 2018; 12:39. DOI: 10.3389/fnbeh.2018.00039.
41.
Barata-AntunesS, TeixeiraFG, Mendes-PinheiroB, et al.Impact of aging on the 6-OHDA-induced rat model of Parkinson's disease. Int J Mol Sci, 2020; 21. DOI: 10.3390/ijms21103459.
42.
Padovan-NetoFE, EcheverryMB, ChiavegattoS, et al.Nitric oxide synthase inhibitor improves de novo and long-term l-DOPA-induced dyskinesia in hemiparkinsonian rats. Front Syst Neurosci, 2011; 5:40. DOI: 10.3389/fnsys.2011.00040.
43.
JoeEH, ChoiDJ, AnJ, et al.Astrocytes, microglia, and Parkinson's disease. Exp Neurobiol, 2018; 27:77–87. DOI: 10.5607/en.2018.27.2.77.
44.
ChunH, ImH, KangYJ, et al.Severe reactive astrocytes precipitate pathological hallmarks of Alzheimer's disease via H2O2– production. Nat Neurosci, 2020; 23:1555–1566. DOI: 10.1038/s41593-020-00735-y.
45.
Ostrerova-GoltsN, PetrucelliL, HardyJ, et al.The A53T alpha-synuclein mutation increases iron-dependent aggregation and toxicity. J Neurosci, 2000; 20:6048–6054. DOI: 10.1523/JNEUROSCI.20-16-06048.2000.
46.
FlagmeierP, MeislG, VendruscoloM, et al.Mutations associated with familial Parkinson's disease alter the initiation and amplification steps of alpha-synuclein aggregation. Proc Natl Acad Sci U S A, 2016; 113:10328–10333. DOI: 10.1073/pnas.1604645113.
47.
CabinDE, ShimazuK, MurphyD, et al.Synaptic vesicle depletion correlates with attenuated synaptic responses to prolonged repetitive stimulation in mice lacking alpha-synuclein. J Neurosci, 2002; 22:8797–8807. DOI: 10.1523/JNEUROSCI.22-20-08797.2002.
48.
HuangM, WangB, LiX, et al.Alpha-synuclein: a multifunctional player in exocytosis, endocytosis, and vesicle recycling. Front Neurosci, 2019; 13:28. DOI: 10.3389/fnins.2019.00028.
49.
AbeliovichA, SchmitzY, FarinasI, et al.Mice lacking alpha-synuclein display functional deficits in the nigrostriatal dopamine system. Neuron, 2000; 25:239–252. DOI: 10.1016/s0896-6273(00)80886-7.
QingX, WalterJ, JarazoJ, et al.CRISPR/Cas9 and piggyBac-mediated footprint-free LRRK2-G2019S knock-in reveals neuronal complexity phenotypes and α-Synuclein modulation in dopaminergic neurons. Stem Cell Res, 2017; 24:44–50. DOI: 10.1016/j.scr.2017.08.013.
52.
LeeJ, BayarsaikhanD, ArivazhaganR, et al.CRISPR/Cas9 edited sRAGE-MSCs protect neuronal death in Parkinson's disease model. Int J Stem Cells, 2019; 12:114–124. DOI: 10.15283/ijsc18110.
53.
BulchaJT, WangY, MaHet al.Viral vector platforms within the gene therapy landscape. Signal Transduct Target Ther, 2021; 6:53. DOI: 10.1038/s41392-021-00487-6.
54.
TambascoN, NigroP, RomoliMet al.A53T in a parkinsonian family: a clinical update of the SNCA phenotypes. J Neural Transm, 2016; 123:1301–1307. DOI: 10.1007/s00702-016-1578-6.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
